Glenmark's Joint Venture Files IND for Solid Tumor Drug with FDA
What happened
Ichnos Glenmark Innovation, a joint venture between Glenmark Pharmaceuticals and Ichnos Sciences, submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) on November 17, 2026, for the experimental cancer drug ISB 2301. The drug is a pentaspecific molecule designed to target solid tumors. The company plans to initiate Phase I clinical trials in 2027, pending regulatory clearance.
Why it matters
The filing advances the development of ISB 2301, a first-in-class molecule designed to address the biological diversity of solid tumors. Successful regulatory clearance and subsequent clinical trials could lead to future market authorization and revenue generation for the joint venture.
Who's involved
- Glenmark PharmaceuticalsFounding partner of the joint venture Ichnos Glenmark Innovation.
- FDARegulatory agency that received the Investigational New Drug application.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Glenmark PharmaceuticalsSpeculative
Could see increased investment in its oncology pipeline following the IND filing.
- AbbVieSpeculative
Might see increased investment in its drug development programs related to the joint venture.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- Glenmark's new cancer drug requires CDER reviewCDER must review Glenmark's new cancer drug application for clinical trials.Likely
- Glenmark's US drug filing could shape EMA's future reviewThe US regulatory progress may influence the EMA's review of ISB 2301.Possible
- US drug progress may influence European Commission's regulatory strategyUS cancer drug progress may influence European Commission's regulatory strategyPossible
- New cancer drug filing could intensify competition for Eli LillyIncreased competition in solid tumor oncology may challenge Eli Lilly's market position.Possible
- New cancer drug filing may increase competition for Merck Sharp & DohmeNew pentaspecific cancer drug could increase competition for Merck Sharp & DohmePossible
Keep exploring
The entities involved
-
Glenmark Pharmaceuticals
Indian multinational pharmaceutical company
Nothing else this week.
- FDA